


**Product Name** : CT1812  
**Cat. No.** : PC-21108  
**CAS No.** : 1802632-22-9  
**Molecular Formula** : C<sub>24</sub>H<sub>33</sub>NO<sub>4</sub>S  
**Molecular Weight** : 431.59  
**Target** : Sigma Receptor  
**Solubility** : 10 mM in DMSO



### Biological Activity

CT1812 (Zervimesine) is a potent, orally active dual **σ1R** and **σ2R** ligand with K<sub>i</sub> of 63 and 8.5 nM respectively, IC<sub>50</sub> of 0.31 μM in neuronal trafficking assays.

CT1812 prevented and reversed trafficking deficits caused by soluble Aβ oligomers (AβOs), but had no effect in the absence of AβOs in neurons.

CT1812 also prevented binding AβO to neuronal receptors, displaced prebound AβO, and was determined by a one-site ELISA assay to have no effect on AβO assembly or AβO dissociation.

CT1812 is an AβO-displacing compound and a potent and highly selective antagonist of the sigma-2 receptor.

CT1812 significantly increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF compared to placebo.

### References

Izzo NJ, et al. *Alzheimers Dement*. 2021 Aug;17(8):1365-1382.

Rishton GM, et al. *ACS Med Chem Lett*. 2021 Aug 9;12(9):1389-1395.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com